Calici, an AI-driven drug discovery platform company led by CEO Jae-Mun Choi, announced on the 16th that it has signed a Memorandum of Understanding (MOU) with Cureverse, a small-molecule innovative drug development biotech led by CEO Sung-Jin Cho, to collaborate on AI-based small-molecule drug discovery.

The partnership aims to enhance the sophistication and efficiency of discovering new innovative drug candidates. By combining Calici’s AI platform with Cureverse’s drug development expertise, the two companies plan to rapidly screen high-quality lead compounds and conduct optimization studies to select final candidate molecules.

Specifically, the collaboration will include:

• Joint research from the early stages of drug development strategy exploration
• Strategic technology and information exchange
• Coordination for global technology transfer following the acquisition of new drug pipelines

CEO Jae-Mun Choi of Calici stated, “We are excited to develop innovative drugs together with Cureverse, a leading biotech group. We will fully leverage Calici’s capabilities to contribute to the success of Cureverse’s drug pipeline.”